Legend Biotech Corporation vs Merck & Company, Inc. — Stock Comparison

LEGN
Legend Biotech Corporation
$23.59
▲ 0.30%
vs
MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
Q·Score Winner
Merck & Company, Inc.
MRK6.7/10vs 5.9/10

Q·Score Breakdown

5.9
Neutral
Overall
6.7
Neutral
0.2
Quality
6.2
7.6
Health
7
5.5
Growth
6.2
9.7
Valuation
7.2
8.3
Sentiment
7.1
LEGN

Consensus analyst target of $57.23 is 143% above current price.

currently unprofitable (-29% margin).

MRK

Forward P/E of 11.5× is low relative to sector peers.

Analyst Consensus

BUY
Target $57.23 (+142.6%)
16 analysts
BUY
Target $129.74 (+15.7%)
27 analysts

Fundamentals

LEGN
MRK
Trailing P/E
31.5×
20.5×
Forward P/E
11.5×
-28.8%
Profit Margin
13.6%
20.0%
Gross Margin
76.6%
-29.1%
ROE
64.2%
Revenue Growth
4.9%
Earnings Growth
0.08
Beta
0.28
Price / Book
$4.4B
Market Cap
$277.0B
$16 – $45
52-Week Range
$73 – $125

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →